Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2022 | 432 | 4.010 |
Why?
|
| Anti-HIV Agents | 14 | 2022 | 102 | 3.170 |
Why?
|
| Pre-Exposure Prophylaxis | 16 | 2022 | 67 | 2.310 |
Why?
|
| HIV-1 | 3 | 2018 | 36 | 1.240 |
Why?
|
| Medication Adherence | 12 | 2022 | 64 | 1.150 |
Why?
|
| Homosexuality, Male | 12 | 2022 | 83 | 0.970 |
Why?
|
| Tenofovir | 4 | 2021 | 9 | 0.860 |
Why?
|
| Transgender Persons | 7 | 2022 | 24 | 0.810 |
Why?
|
| Adenine | 3 | 2019 | 4 | 0.700 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 84 | 0.690 |
Why?
|
| Emtricitabine | 4 | 2022 | 6 | 0.660 |
Why?
|
| Humans | 24 | 2022 | 6794 | 0.610 |
Why?
|
| Rilpivirine | 1 | 2018 | 1 | 0.580 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 1 | 0.580 |
Why?
|
| Tablets | 1 | 2018 | 3 | 0.580 |
Why?
|
| Mentoring | 1 | 2018 | 12 | 0.570 |
Why?
|
| Patient Participation | 1 | 2018 | 32 | 0.550 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 45 | 0.490 |
Why?
|
| Adult | 14 | 2021 | 2113 | 0.440 |
Why?
|
| Male | 17 | 2022 | 3671 | 0.440 |
Why?
|
| Sexual and Gender Minorities | 4 | 2022 | 49 | 0.380 |
Why?
|
| Sexual Behavior | 4 | 2022 | 100 | 0.380 |
Why?
|
| Sexual Partners | 3 | 2019 | 49 | 0.330 |
Why?
|
| Unsafe Sex | 2 | 2020 | 21 | 0.310 |
Why?
|
| Text Messaging | 4 | 2022 | 14 | 0.300 |
Why?
|
| Female | 11 | 2022 | 4060 | 0.290 |
Why?
|
| Middle Aged | 6 | 2021 | 2108 | 0.220 |
Why?
|
| Risk-Taking | 3 | 2019 | 77 | 0.220 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2022 | 35 | 0.210 |
Why?
|
| California | 3 | 2022 | 230 | 0.210 |
Why?
|
| Motivational Interviewing | 1 | 2022 | 5 | 0.190 |
Why?
|
| Gender-Based Violence | 1 | 2022 | 3 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 17 | 0.190 |
Why?
|
| Syphilis | 1 | 2022 | 5 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2022 | 19 | 0.180 |
Why?
|
| Organophosphates | 2 | 2019 | 2 | 0.180 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 169 | 0.170 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 5 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2019 | 2 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2019 | 22 | 0.160 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2019 | 2 | 0.150 |
Why?
|
| Bone Remodeling | 1 | 2019 | 6 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 145 | 0.150 |
Why?
|
| Oxazines | 1 | 2018 | 2 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 3 | 0.150 |
Why?
|
| Drug Tolerance | 1 | 2018 | 25 | 0.150 |
Why?
|
| Vitamin D | 1 | 2019 | 45 | 0.140 |
Why?
|
| Piperazines | 1 | 2018 | 21 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 2 | 0.140 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 3 | 0.140 |
Why?
|
| Enema | 1 | 2018 | 2 | 0.140 |
Why?
|
| Gonorrhea | 1 | 2018 | 2 | 0.140 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 3 | 0.140 |
Why?
|
| Rectum | 1 | 2018 | 8 | 0.140 |
Why?
|
| Chlamydia Infections | 1 | 2018 | 8 | 0.140 |
Why?
|
| Health Personnel | 1 | 2018 | 49 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 102 | 0.130 |
Why?
|
| Prodrugs | 1 | 2017 | 2 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 12 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 567 | 0.130 |
Why?
|
| Depression | 1 | 2018 | 128 | 0.130 |
Why?
|
| Bone Density | 1 | 2017 | 25 | 0.130 |
Why?
|
| Kidney | 1 | 2017 | 184 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 268 | 0.110 |
Why?
|
| United States | 3 | 2021 | 1019 | 0.100 |
Why?
|
| Incidence | 2 | 2022 | 197 | 0.080 |
Why?
|
| Adolescent | 2 | 2021 | 869 | 0.070 |
Why?
|
| Viral Load | 1 | 2022 | 26 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 25 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 28 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 9 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 54 | 0.050 |
Why?
|
| Prevalence | 1 | 2022 | 259 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 46 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 36 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 35 | 0.040 |
Why?
|
| Condoms | 1 | 2020 | 41 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 82 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 35 | 0.040 |
Why?
|
| Capsules | 1 | 2019 | 1 | 0.040 |
Why?
|
| Wireless Technology | 1 | 2019 | 1 | 0.040 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 3 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 83 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 54 | 0.040 |
Why?
|
| Los Angeles | 1 | 2020 | 321 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 31 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 153 | 0.040 |
Why?
|
| Deglutition | 1 | 2019 | 40 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 89 | 0.040 |
Why?
|
| Procollagen | 1 | 2019 | 1 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2019 | 23 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 66 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 50 | 0.040 |
Why?
|
| Directive Counseling | 1 | 2019 | 4 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 15 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 3 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 165 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2019 | 44 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 75 | 0.040 |
Why?
|
| Chlamydia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Rectal Diseases | 1 | 2018 | 3 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 82 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2019 | 331 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 65 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 214 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2019 | 681 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 285 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 767 | 0.030 |
Why?
|